immunotherapy

Displaying 1 - 10 of 10

Study identifies biomarker for breast cancer response to immunotherapy

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Related Categories: 
Health and Medicine Research American Association for Cancer Research breast cancer Clinical Cancer Research Department of Medicine immunotherapy Justin Balko pathology microbiology and immunology

Project seeks new way to assess immunotherapy effectiveness

GE Healthcare has awarded researchers in the Vanderbilt University Institute of Imaging Science (VUIIS) $2.5 million in funding to develop a positron emission tomography (PET) tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.

Related Categories: 
Research GE Healthcare H. Charles Manning imaging immunotherapy radiology and radiological sciences Vanderbilt Institute of Imaging Science

Discovery points to new cancer immunotherapy option

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

Related Categories: 
Amy and Barry Baker Lab cancer immunotherapy Cancer Research checkpoint inhibitors department of otolaryngology Flow Cytometry Shared Resource immune system immunotherapy t cell Vanderbilt Ingram Cancer Center Vanderbilt Institute for Infection Immunology and Inflammation Young Kim

Breast cancer-killing RIG

Immune checkpoint inhibitors — cancer therapies that remove the “brakes” on the adaptive anti-tumor immune response — have had remarkable success in melanoma and lung cancer.

Related Categories: 
Health and Medicine Research antivirus Basic Sciences breast cancer cancer cancer biology immunotherapy Cancer Research checkpoint inhibitors Department of Cell and Developmental Biology immune response national science foundation Rebecca Cook Vanderbilt Ingram Cancer Center

GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment

GE Healthcare partners with Vanderbilt University on precision immunotherapy apps

Related Categories: 
Partnership Vanderbilt University Medical Center GE cancer immunotherapies GE Healthcare positron-emission tomography immunotherapy

Immunotherapies linked to specific heart complications

Immunotherapies linked to specific heart complications

Related Categories: 
adverse drug reactions cancer immunotherapy cancer checkpoint inhibitors Department of Medicine douglas johnson immunotherapy James C. Bradford Jr. Melanoma Fund Javid Moslehi NCI NIH The Lancet Oncology Vanderbilt Cardio-Oncology Vanderbilt Ingram Cancer Center

Mary Kay Foundation grant to bolster immunotherapy research

An immunotherapy research initiative at Vanderbilt University Medical Center is among those being supported by the Mary Kay Foundation, which has announced $1.2 million in funding that will be equally shared among 12 cancer research institutions.

Related Categories: 
charles caskey immunotherapy radiology radiology and radiological sciences

Team’s findings show glutamine metabolism affects T cell signaling

Team’s findings show glutamine metabolism affects T cell signaling

Related Categories: 
Autoimmune disease cancer immunotherapy CAR T Therapy Cell Cell Metabolism center for immunobiology glutamine immunotherapy inflammation jeffrey rathmell NCI NHLBI NIH. Pathology microbiology and immunology t cell

Study tracks incidence, timing of immunotherapy-related deaths

Study tracks incidence, timing of immunotherapy-related deaths

Related Categories: 
checkpoint inhibitors douglas johnson immunotherapy JAMA Oncology NIH Vanderbilt Ingram Cancer Center

Study seeks to boost breast tumor immune response

Immunotherapy, which harnesses the power of the immune system, is one of the most promising forms of cancer therapy and has been shown to work well against some types of cancer. But in early studies, breast cancer has proven to be largely resistant to immunotherapies, which are effective in only about 5 to 10 percent of patients whose tumors have spread or metastasized.

Related Categories: 
Justin Balko VICC Vanderbilt-Ingram Cancer Center immunotherapy molecular oncology Vanderbilt University Vanderbilt University Medical Center